BillionToOne (BLLN) Raises 2026 Revenue Guidance to $460M–$470M

BillionToOne reported Q3 2026 revenue of $123.0M, up 47% YoY, with net income of $17.4M. The company raised its 2026 revenue guidance to $460.0M–$470.0M from $450.0M–$465.0M. According to the company, this reflects continued growth and profitability.

Original reporting
Published Nov 4, 2026, 9:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 9:11 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
BillionToOne (BLLN) Raises 2026 Revenue Guidance to $460M–$470M — source image
Decision brief

The 30-second read

$BLLNBullishHigh
01

Why it matters

The guidance lift is a primary earnings disclosure that can move the stock in after‑hours trading and set the tone for the next quarter.

02

Market read

Fresh earnings guidance for a growth‑stage tech firm; likely catalyst for short‑term price movement.

03

What to watch

Potential cash‑burn or dilution from future financing rounds could offset revenue growth.

Relevance 7/10Novelty 8/10Timing: after-hours

Background

BillionToOne reported Q3 2026 results with revenue up 47% YoY and net income rising sharply, prompting an upward revision of full‑year revenue guidance.

Company-level read

Ticker impact

$BLLNBullishHigh confidence
Context

BillionToOne raised its 2026 revenue guidance to $460M‑$470M from $450M‑$465M.

Expected impact

upward pressure as the market prices in higher revenue expectations

Evidence & confidence

The company reported a 47% YoY revenue increase and lifted full‑year guidance, a fresh material fact that traders can act on immediately.

Market effects

Positive for the AI‑software/services sector as the guidance beat expectations.

Minor impact on US micro‑cap segment.

Limited to investors tracking high‑growth tech microcaps.

Counterpoint

The guidance raise may already be priced in; any miss on Q4 could trigger a sell‑off.

Key entities

  • BillionToOne

    US‑listed micro‑cap providing AI‑driven data solutions.

Related articles

$BLLNMed

BillionToOne: Q3 Earnings Snapshot

BillionToOne (BLLN) reported Q3 earnings of $17.4M, or 32 cents per share, beating estimates of 16 cents. Revenue was $123M, exceeding forecasts of $116.2M. The company expects full-year revenue between $460M and $470M. Shares have risen 39% YTD.

$BLLNMed

BillionToOne reports Q3 EPS 32c, consensus 30c

BillionToOne (BLLN) reported Q3 EPS of 32 cents, beating the consensus of 30 cents, and revenue of $122.98M, exceeding the consensus of $115.8M. The company highlighted growth, profitability, and clinical validation of its tests. CEO Atay announced the upcoming launch of Northstar Clear. Guggenheim raised its price target to $128 from $125.

$BLLNHighAI 8/10

BillionToOne Reports Third Quarter 2026 Results and Raises 2026 Revenue Guidance

BillionToOne, Inc. (BLLN) filed an SEC Form 8-K — Results of Operations and Financial Condition. BillionToOne Reports Third Quarter 2026 Results and Raises 2026 Revenue Guidance MENLO PARK, CA, November 4, 2026 - BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all,

$BLLNLow

BillionToOne's Northstar Response Shows High Concordance In Advanced Cancer Study

BillionToOne (BLLN) published a study showing its Northstar Response liquid biopsy assay had high concordance with a commercial ctDNA assay in advanced cancer patients. The study of 61 patients found 94% agreement in tumor burden change direction, with Northstar Response aligning with clinical ground truth in discordant cases. The assay detects disease progression even when tumors evolve post-biopsy. BLLN shares closed at $22.71, down 0.79%.